Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Duquesne Family Office LLC

Duquesne Family Office LLC boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 100.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,265 shares of the company's stock after purchasing an additional 43,300 shares during the period. Duquesne Family Office LLC owned about 0.07% of Vaxcyte worth $7,062,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Wells Fargo & Company MN increased its stake in Vaxcyte by 53.7% in the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after purchasing an additional 25,257 shares in the last quarter. Diversified Trust Co purchased a new position in Vaxcyte in the 4th quarter valued at approximately $1,433,000. China Universal Asset Management Co. Ltd. increased its stake in Vaxcyte by 23.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after purchasing an additional 4,962 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in Vaxcyte by 53.7% in the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock valued at $33,860,000 after purchasing an additional 144,516 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in Vaxcyte by 70.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after purchasing an additional 246,049 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares in the company, valued at approximately $11,351,794.37. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Guggenheim reiterated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Needham & Company LLC reissued a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. The Goldman Sachs Group dropped their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Bank of America dropped their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Cantor Fitzgerald assumed coverage on Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating for the company. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vaxcyte has an average rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Stock Up 2.4%

Shares of PCVX stock traded up $0.74 during mid-day trading on Monday, hitting $31.90. 956,708 shares of the company's stock were exchanged, compared to its average volume of 1,308,439. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The stock has a 50-day simple moving average of $46.66 and a two-hundred day simple moving average of $74.19. The stock has a market cap of $4.11 billion, a price-to-earnings ratio of -6.95 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period last year, the business posted ($0.85) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.